DAYTON MISFELDT - Corporate Board Profile

Viracta Therapeutics, Inc.

Filing Date	Source Excerpt
2009-05-20	Dayton Misfeldt is an Investment Partner at Bay City Capital LLC, a venture capital firm, and focuses on biopharmaceutical investment opportunities. ... On April 3, 2009, Mr. Fust resigned as a member of the Nominating and Corporate Governance Committee and Mr. Misfeldt was appointed as a member of such Committee. ... The Compensation Committee is chaired by Mr. Misfeldt, and also includes Messrs. Hurwitz and Fust. ... The following table provides current membership and meeting information for 2008 for each of the committees of the Board: ... Dayton Misfeldt (2) Audit Committee (Chairperson), Compensation Committee, Nominating and Corporate Governance Committee.
2010-04-29	Dayton Misfeldt is an Investment Partner at Bay City Capital LLC. Mr. Misfeldt was appointed to the Board on April 3, 2009. Mr. Misfeldt waived his cash compensation in 2009. Mr. Misfeldt's total compensation for 2009 was $6,149.
2011-04-21	Dayton Misfeldt is an Investment Partner at Bay City Capital LLC, a venture capital firm, and focuses on biopharmaceutical investment opportunities. ... Our Compensation Committee is chaired by Mr. Misfeldt, and also includes Messrs. Hurwitz and Fust. ... The following table sets forth the compensation information for our non-employee directors, as well as Dr. Young, the current Chairman of our Board and former Executive Chairman, for the year ended December 31, 2010. ... Dayton Misfeldt Fees Earned or Paid in Cash $0, Option Awards $5,393, Total $5,393.
2012-04-23	Dayton Misfeldt is an Investment Partner at Bay City Capital LLC. Mr. Misfeldt was appointed as a director pursuant to the Investor Rights Agreement executed in connection with Bay City Capital's purchase of our securities in the Private Placement. The Board has concluded that Mr. Misfeldt should serve on our Board due to his financial expertise and strong understanding of the biotechnology industry. Director Compensation Table shows total compensation of $72,690.
2013-04-25	Dayton Misfeldt is an Investment Partner at Bay City Capital LLC, a venture capital firm, and focuses on biopharmaceutical investment opportunities. ... The Compensation Committee is chaired by Mr. Misfeldt, and also includes Mr. Fust. ... The Nominating Committee is chaired by Dr. Pearce and also includes Mr. Misfeldt, each of whom is independent. ... The following table sets forth the compensation information for our non-employee directors for the year ended December 31, 2012. ... Dayton Misfeldt total compensation $50,480.
2014-04-24	Dayton Misfeldt serves as Chairman of the Compensation Committee and is a member of the Audit and Nominating and Corporate Governance Committees. The compensation table shows total compensation of $106,046 for 2013.
2015-04-28	Dayton Misfeldt is an Investment Partner at Bay City Capital LLC, a venture capital firm, and focuses on biopharmaceutical investment opportunities. Prior to joining Bay City Capital in May 2000, Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. Mr. Misfeldt has also worked as a Project Manager at LifeScience Economics. Mr. Misfeldt currently serves on the board of directors of Interleukin Genetics, Inc., a genetic testing healthcare company. Mr. Misfeldt received a B.A. in Economics from the University of California, San Diego. The Board has concluded that Mr. Misfeldt should serve on our Board due to his financial expertise and strong understanding of the biotechnology industry, which the Board believes makes him an important resource for the Board as it assesses both financial and strategic decisions. Director Compensation Table: Dayton Misfeldt Fees Earned or Paid in Cash ($): $60,000, Option Awards ($): $87,038, Total ($): $147,038.
2016-04-25	Dayton Misfeldt serves on the Audit Committee, Compensation Committee (Chairman), and Nominating and Corporate Governance Committee. The Director Compensation Table shows total compensation of $144,652.
2017-04-20	Dayton Misfeldt is an Investment Partner at Bay City Capital LLC. ... The Board has concluded that Mr. Misfeldt should serve on our Board due to his financial expertise and strong understanding of the biotechnology industry. ... The following table sets forth the compensation information for our non-employee directors for the year ended December 31, 2016. Dayton Misfeldt received total compensation of $81,740.
2018-04-25	Dayton Misfeldt has served as our Interim Chief Executive Officer since January 1, 2018. ... The Board has concluded that Mr. Misfeldt should serve on our Board due to his financial expertise and strong understanding of the biotechnology industry. ... On December 2, 2017, the Board appointed Dayton Misfeldt as interim Chief Executive Officer. Mr. Misfeldt stepped down from each of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective December 31, 2017. ... Dayton Misfeldt 65,000 fees earned, 228,075 option awards, total 293,075.
2019-04-12	Dayton Misfeldt has served as our Interim Chief Executive Officer since January 1, 2018. ... The aggregate grant date fair value of option awards and director fees received by Mr. Misfeldt for his services as a director are disclosed in the Summary Compensation Table. ... Summary Compensation Table: Dayton Misfeldt 2018 Total $574,939.
2020-04-28	Dayton Misfeldt has served as our Interim Chief Executive Officer since January 1, 2018. The Board has concluded that Mr. Misfeldt should serve on our Board due to his financial expertise. The Director Compensation Table and Summary Compensation Table show total compensation of $339,886 for 2019, including director fees and option awards. He is not an independent director.